Pipeline Programs
CGT Companies Tracked
Manufacturing Facilities
The global biosimilar monoclonal antibodies market size was estimated at USD 16.05 billion in 2025 and is predicted to increase from USD 19.78 billion in 2026 to approximately USD 129.61 billion by 2035, expanding at a CAGR of 23.23% from 2026 to 2035.
The biosimilar monoclonal antibodies market is growing due to increasing applications of these antibodies in oncology autoimmune and inflammatory diseases, ophthalmology, and other areas.
The biosimilar monoclonal antibodies market is growing due to growing access and lower expenses for patients and medical care systems. Monoclonal antibodies (mAbs) are a main class of recombinant deoxyribonucleic acid (rDNA) technology-based biotherapeutic products that attain outstanding achievement in treating many life-threatening and long-term diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar antibodies make it possible to research the biological effects of a drug without requiring the sourcing of expensive pharmaceutical-grade therapeutics.
Biosimilar monoclonal antibodies are highly similar versions of approved reference biologic antibodies that demonstrate comparable safety, efficacy, and quality while offering more cost-effective treatment options for cancer, autoimmune, and inflammatory diseases. The biosimilar monoclonal antibodies market is expanding due to the expiration of patents for blockbuster biologics, increasing demand for affordable biologic therapies, and rising prevalence of chronic diseases. Key trends include greater physician acceptance, expanding regulatory approvals, and broader adoption across oncology and immunology. Technological advancements in cell line engineering, single-use bioprocessing systems, advanced analytical characterization, and AI-enabled biomanufacturing are improving production efficiency and product consistency. Future opportunities are driven by emerging markets, increasing healthcare cost-containment initiatives, strategic collaborations, and continuous investment in biosimilar research, manufacturing capacity, and commercialization worldwide.
AI is transforming the biosimilar monoclonal antibodies market by accelerating R&D, significantly reducing development timelines and costs. Machine learning models optimize antibody characterization, predict structural similarities to reference products, and enhance manufacturing processes. AI-driven predictive analytics minimize manufacturing waste, ensure consistent quality, and assist in regulatory compliance. Furthermore, AI helps in navigating market penetration, making biosimilars more affordable and accessible, thereby enhancing market competition and patient access.
Advanced Antibody Engineering:
Antibody engineering allows the manufacturing of antibodies with high specificity, stability, affinity, and low immunogenicity, while also engineering new functionalities beyond those of natural antibodies, therefore increasing their uses in disease treatment and diagnostics.
Next-Gen Sequencing (NGS):
Next-generation sequencing (NGS) provides an affordable service with increased read depth, enabling an inclusive understanding of diversity.
Multispecific Antibodies:
Multispecific antibodies are evolved to engage two or more different targets, offering medicinal advantages over conventional monoclonal antibodies. These include improved recruitment of immune effector cells, concurrent modulation of multiple signalling pathways, and introduction of apoptosis.
| Key Elements | Scope |
| Market Size in 2026 | USD 19.78 Billion |
| Projected Market Size in 2035 | USD 129.61 Billion |
| CAGR (2026 - 2035) | 23.23% |
| Leading Region | North America by 41% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Type, By Indication, By End User, By Region |
| Top Key Players | Biocon, Shanghai Henlius Biotech, Inc., Amgen Inc., Biogen, Celltrion Healthcare Co., Ltd., Novartis AG |
| Segments | Shares % |
| Infliximab | 26% |
| Adalimumab | 22% |
| Rituximab | 18% |
| Trastuzumab | 16% |
| Bevacizumab | 12% |
| Others | 6% |
Which Type Led the Biosimilar Monoclonal Antibodies Market in 2025?
In 2025, the infliximab segment held the dominant market share by 26%, as it is applied alone or in combination with other various treatments to lower the symptoms and prevent the progression of moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, and active ankylosing spondylitis. It works to boost and improve the immune system. The efficiency of infliximab demonstrated the practicality of monoclonal antibody therapies in targeting specific molecules involved in disease pathology.
Adalimumab
Whereas the adalimumab segment is the fastest-growing in the market, as these are used to lessen swelling by working on the immune system. Adalimumab is applied to treat inflammation of the joints, such as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and active enthesitis-related arthritis, and skin conditions such as plaque psoriasis and hidradenitis suppurativa. Adalimumab efficiently reduces inflammation, averts tissue damage, and progresses disease management, leading to better long-term results for patients.
| Segments | Shares % |
| Oncology | 48% |
| Autoimmune Diseases | 42% |
| Others | 10% |
Why did the Oncology Segment Dominate the Market in 2025?
The oncology segment is dominant in the biosimilar monoclonal antibodies market by 48% share in 2025, and is expected to register the highest CAGR during the forecast period, as it has massive strength advantages in managing cancer. They introduce competition into the drug development process, which leads to investment savings for patients and accelerates the development of novel treatments.
| Sites of Cancer | Estimated New Cases | Estimated Deaths |
| All sites | 2,041,910 | 618,120 |
| Digestive system | 362,200 | 174,520 |
| Respiratory system | 245,700 | 130,200 |
| Bones & joints | 3,770 | 2,190 |
| Skin | 112,690 | 14,110 |
| Breast | 319,750 | 42,680 |
| Genital system | 444,610 | 71,510 |
| Segments | Shares % |
| Hospitals | 62% |
| Cancer Treatment Centers | 26% |
| Others | 12% |
Why did the Hospital Segment Dominate the Market in 2025?
The hospital segment is dominant in the biosimilar monoclonal antibodies market by 62% in 2025 and is expected to register the highest CAGR during the forecast period, as biosimilar monoclonal antibodies present a significant advancement in aligning medical care innovation with medical care affordability. Investigators use mAbs (biosimilars) as tools to research novel therapies and uncover efficacy in off-target applications. Biosimilars provide affordable treatment options that support contain the in-healthcare expenditure.
In 2025, North America led the biosimilar monoclonal antibodies market with share of 41%, as the growing prevalence of long term diseases like cancer and autoimmune disorders, and increasing demand for personalized medicine and targeted therapy. The FDA has approved 76 biosimilars, corresponding to a small fraction of approved biologics. There are more than 30,000 approved generics, increasing the number of approved brand drugs, which drives the growth of the market.
For Instance,
U.S. Market Trends
In the U.S. presence of significant pharmaceutical organizations such as Pfizer, Amgen, and Sandoz is headquartered or heavily active in this region, increasing product advancement and introductions. Development in mAb technology is increasing advances in oncology, autoimmune disorders, and infectious diseases. Around 6 in 10 Americans live with at least one chronic disease, with cardiac disease and diabetes, which increases the need for biosimilar monoclonal antibodies.
Canada’s Supportive Biosimilar Policies Are Driving Monoclonal Antibodies Market Growth
Canada’s biosimilar monoclonal antibodies market is growing significantly due to supportive government policies promoting biosimilar adoption, increasing demand for cost-effective biologic therapies, and the rising burden of cancer and autoimmune diseases. Expanding provincial and growing transition programs, strong regulatory oversight, and growing physician confidence are accelerating market uptake. Additionally, investments in biopharmaceutical research and collaborations between healthcare providers and manufacturers are supporting continued market expansion.
Asia Pacific is set to experience rapid growth in the biosimilar monoclonal antibodies market by 20% share, as Asia accounts for 22% of worldwide healthcare investment, with chronic conditions like diabetes and cancer disproportionately affecting the region, which drives the growth of the market. Increasing government support, such as South Korea's Ministry of Health and Welfare (MOHW), will implement the Pharmaceutical Pricing System Improvement Plan.
For Instance,
India Market Trends
The Indian government has set a minimum import price (MIP) for some key pharmaceutical inputs to combat aggressive undercutting and dumping from Chinese manufacturers, which increases the demand for biosimilar monoclonal antibodies.
China Expanding Biopharmaceutical Innovation Is Fueling Biosimilar Monoclonal Antibodies Market Growth
China’s biosimilar monoclonal antibodies market is growing notably due to rapid expansion of the domestic biopharmaceutical industry, increasing prevalence of cancer and autoimmune diseases, and strong government support for biologic drug development. Growing regulatory approvals, rising investments in advanced biomanufacturing, and expanding access to affordable biologic therapies are accelerating adoption. Additionally, increasing clinical research and strategic partnerships are strengthening the country’s biosimilar ecosystem.
Europe is experiencing substantial growth in the biosimilar monoclonal antibodies market by 29% share, as biosimilars continue to be an important part of the European medical system, and it balances pharmaceutical investment by creating savings for payers, generating headroom for novelty, and increasing access to biologic therapy for patients, which drives the growth of the market.
UK Market Trends
The UK has a significant integration of proactive regulatory streamlining (MHRA), strong NHS-led cost-containment and advance approches, enhance physician confidence, and leveraging post-Brexit government autonomy. NHS England is targeting £150 million in savings via the rapid adoption of biosimilar adalimumab.
Germany String Biopharmaceutical Ecosystem Is Accelerating Biosimilar Monoclonal Antibodies Market Growth
Germany’s biosimilar monoclonal antibodies market is growing notably due to its advanced biopharmaceutical manufacturing capabilities, increasing adoption of biosimilars in oncology and immunology, and supportive healthcare reimbursement policies. Strong regulatory confidence, extensive clinical expertise, and rising demand for cost-efficient biologic therapies are driving market expansion. Additionally, continuous investments in biologics research and strategic collaborations between pharmaceutical companies are fostering innovation and broader biosimilar adoption.
The market in South America is rapidly growing due to patent expirations for major biologics, a demand for affordable chronic illness treatments, and government cost-control initiatives. Streamlined regulations, increased physician confidence in biosimilars, and enhanced local manufacturing are accelerating growth. The rise in cancer and autoimmune diseases is driving the need for cost-effective therapies like rituximab, trastuzumab, and adalimumab. Public health systems favor tender-based purchasing, promoting cheaper biosimilars over expensive originals. Investments in biotechnology and partnerships between local and international firms are enhancing regional manufacturing.
Brazil Market Trends
Brazil is the leader in the Latin American market, fueled by high public health demand, government strategies for local production, and a robust regulatory framework from ANVISA. The SUS oversees most biological products, steering the market towards affordable biosimilars, often influenced by legal challenges over high medication costs. Public-private partnerships (PPPs) between state-owned and private companies bolster local manufacturing and technology transfer, crucial for market dominance. Local companies like Blau Farmacêutica have successfully created advanced biosimilars, such as pembrolizumab. Brazil is the primary growth engine for Latin America's biologics market due to its infrastructure, economic scale, and strategic advantages.
The biosimilar monoclonal antibodies market in the Middle East and Africa is expanding by 4% share due to the need for affordable chronic illness treatments, increased healthcare spending, and supportive regulations. Key drivers include rising cancer and autoimmune disease rates, patent expirations on major biologics, and the demand for cost-effective alternatives to improve patient access. The growing number of patients with cancer and chronic conditions like diabetes and arthritis heightens the demand for affordable biologic therapies. Biosimilars offer significant savings over branded biologics, helping to lower healthcare costs. The expiration of patents on expensive monoclonal antibodies allows for the introduction of more affordable biosimilars, while improved healthcare infrastructure and a focus on biotechnology support local production and acceptance.
UAE Market Trends
In the UAE, the market is shaped by a high incidence of chronic diseases, a demand for cost-effective treatments, and strong government support for biotechnology. Factors include advanced healthcare systems in Dubai and Abu Dhabi, quick regulatory approvals, and increased local manufacturing investment. The rise in cancer and autoimmune diseases drives the need for affordable biologics, with biosimilars providing economical alternatives that enhance healthcare sustainability and patient access. Supportive policies, such as fast-tracked regulatory approvals and local production investments, further boost the market, positioning the UAE as a key pharmaceutical hub in the MENA region.
R&D:
Manufacturing Processes:
Patient Services:
| Company | Headquarters | Latest Update |
| Biocon | India | In December 2025, Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced a settlement agreement with Amgen Inc. that clears the path for the commercialization of its Denosumab biosimilars in Europe and the rest of the world. |
| Shanghai Henlius Biotech, Inc. | China | In December 2025, Shanghai Henlius Biotech, Inc. announced that the investigational new drug (IND) application for its HLX18, a proposed nivolumab biosimilar independently developed by the company, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain resected solid tumors. |
| Amgen Inc. | United States | In April 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD). |
| Biogen | United States | In November 2025, Biogen will highlight new Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference. |
| Celltrion Healthcare Co., Ltd. | South Korea | In September 2025, Celltrion’s Omlyclo, the first omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries. |
| Novartis AG | Switzerland | In September 2025, Novartis acquired Tourmaline Bio, complementing its cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease. |
In July 2024, “The availability of tocilizumab biosimilar represents a great opportunity to reduce treatment costs, contributing to health-care budget sustainability, improved patient access, and lower disease burden,” said Taehun Ha, vice president and Europe Division head at Celltrion.
Strengths
Weakness
Opportunities
Threat
By Type
By Indication
By End User
By Region
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
